X
X

Mysore

Home / Research & Trials / Mysore

Mysore
Sl. No Principal Investigator’s Name Study Title Phase Protocol ID Indication Study Status Contact person & Phone Number
1 Dr. Srinivas K G A Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) Phase 3 D967UC00001 “HER2-positive Metastatic Breast Cancer” Ongoing “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”
2 Dr. Srinivas K G A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) Phase 3 D9106C00001 Lung Cancer Ongoing “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”
3 Dr. Srinivas K G A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) Phase 3 D3614C00001 Triple Negative Breast Cancer Ongoing “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”
4 Dr. Srinivas K G A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer. (NILE) Phase 3 D933SC00001 Urothelial Cancer close out will be done soon “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”
5 Dr. Srinivas K G “A randomised, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of DRL_RI with MabThera® in subjects with previously untreated, Stage II-IV, CD20-positive, low tumour burden follicular lymphoma” Phase 3 RI-01-006 Follicular Lymphoma Ongoing “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”
6 Dr. Srinivas K G A Phase Ib/III Study of Capivasertib Plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) Phase 3 D3614DC00001 “(HR+/HER2-) Metastatic Breast Cancer” Waiting for site Initiation “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”
7 Dr. Vishwjeeth K Pai Multiomics approach to identify early detection biomarkers – A multi cancer effort in India, (Version No. 01, dated 22nd March, 2022) NA “Breast, cervix, colorectal, esophagus, lung, oral, stomach and ovary” Waiting for site Initiation “Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276”

To get in touch with the Clinical Trials Team at HCG, please call on +91 80 4020 6000 (extn: 6058)

Research and Trials

To know more about facilities available for patients at HCG

HCG Call Icon